Content
All Posts > Content under Healthcare
Johnson & Johnson Slides On Top-Line Miss, Disappointing Drug Sales, Soft Outlook
Article By:
Tyler Durden
Read
Tuesday, January 24, 2017 7:46 AM EDT
Johnson & Johnson reported strong earnings, with EPS of $1.58 coming stronger than the $1.56 consensus expectation, despite revenue of $1.81BN missing consensus of $18.28BN.
In this article: JNJ
Year Of The Rooster
Article By:
Marvin R Clark
Read
Monday, January 23, 2017 11:48 PM EDT
President Trump is expected to sign an executive order as early as today – intended to renegotiate NAFTA, the free trade agreement between the United States, Canada and Mexico.
In this article: AET, BA, CAT, CCS, CI, CVX, F, HAL, HUM, IBM, JNJ, KR, MCD, MMM, T, VZ, AAPL, GOOG, INTC, MSFT, YHOO, BGEN, ANTM
How Will JNJ Investors React To Earnings?
Article By:
WhisperNumber
Read
Monday, January 23, 2017 5:51 PM EDT
Johnson & Johnson is expected to report earnings on Tuesday, January 24th, before market open. The whisper number is $1.50, six cents behind the analysts' estimate and showing no confidence.
In this article: JNJ
AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug
Article By:
KKD Healthcare Analytics
Read
Monday, January 23, 2017 12:01 PM EDT
AbbVie company has announced its decision to hike the price of its Humira drug by over 8%.
In this article: ABBV
Key Events In The Coming Week: All Eyes On Trump's First Actions
Article By:
Tyler Durden
Read
Monday, January 23, 2017 9:34 AM EDT
The key economic releases this week are durable goods and GDP on Friday. On the political front, the focus is on the first actions of the Trump administration including moves on TPP and NAFTA.
Futures, Dollar Slide; European Stocks At 3-Week Lows As "Trump Reality Sets In"
Article By:
Tyler Durden
Read
Monday, January 23, 2017 8:10 AM EDT
Monday has seen a modest case of buyer's remorse, with European stocks sliding, Asian shares mixed and U.S. futures lower as the dollar weakened for the 3rd consecutive day to a six-week low, dropping as much as 1% against the Yen.
Goldman: "All Our Clients Are Confused And Unsettled"
Article By:
Tyler Durden
Read
Sunday, January 22, 2017 5:52 PM EDT
Markets "bought" the election. Now the question is whether they will sell the inauguration. That is the take from the latest weekly letter by Goldman's chief strategist David Kostin, who says that "investor angst is high."
A Quick Look At Recro Pharma
Article By:
KKD Healthcare Analytics
Read
Sunday, January 22, 2017 12:07 PM EDT
Recro Pharma develops non-opioid drugs for pain management. REPH is targeting an NDA this year for its fast-acting IV version of Meloxicam, a well-known NSAID whose oral version just takes too long to work, but has been shown to be effective.
In this article: REPH
Bribery Alert
Article By:
Vivian Lewis
Read
Sunday, January 22, 2017 10:04 AM EDT
SQM will pay $30.5m and enter into a deferred prosecution agreement to resolve civil and criminal matters related to improper payments to Chilean politicians over the government's mining plans, federal authorities said Friday.
Q4 Earnings Growth The Highest In 8 Quarters
Article By:
Sheraz Mian
Read
Saturday, January 21, 2017 6:44 PM EDT
The Q4 earnings season has gotten off to a good start, with earnings and revenue growth tracking above other recent periods and on track to reach the highest level in eight quarters.
Week In Review: WuXi AppTec Acquires HD Biosciences In China CRO Tieup
Article By:
ChinaBio® Today
Read
Saturday, January 21, 2017 1:56 PM EDT
New Century Healthcare, a Beijing operator of children's clinics/hospitals and a recently acquired women's hospital, completed a $114 million IPO in Hong Kong. The transaction was priced at the middle of the expected range.
In this article: AZN
Abbott Laboratories Continues The Launch Of New Products, Stock Rises
Article By:
KKD Healthcare Analytics
Read
Friday, January 20, 2017 12:36 PM EDT
Abbott Laboratories announced that it has launched its Proclaim DRG Neurostimulation System in Europe.
In this article: ABT
Bristol-Myers Slides After Another Lung Cancer Drug Setback
Article By:
The Fly
Read
Friday, January 20, 2017 12:07 PM EDT
Shares of Bristol-Myers Squibb are sliding after the company announced that it will not pursue an accelerated regulatory path for the Opdivo/Yervoy combination, with research firm Cowen downgrading the stock to Market Perform following the news.
Almost Family Announces Pricing Of Upsized Offering Of 3,000,000 Shares Of Common Stock
Article By:
NASDAQ GlobeNewswire
Read
Thursday, January 19, 2017 11:45 PM EDT
Almost Family, Inc. today announced that it has priced its upsized underwritten public offering of 3,000,000 shares of its common stock at a price of $44.50 per share.